Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Rabies shot reveals immune secrets in CAR-T cancer survivors

NCT ID NCT04410900

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed phase 1 trial gave the rabies vaccine to 49 people who had previously received CAR-T therapy for B-cell cancers, along with healthy volunteers for comparison. The goal was to see if their immune systems could mount a normal response to a vaccine. By measuring rabies antibodies in the blood, researchers hope to learn how well the immune system recovers after CAR-T treatment, which could guide future infection prevention.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Rabies vaccine (Imovax Rabies)
What this could lead to
If successful, this study could help doctors understand how well the immune system works after CAR-T therapy, leading to better infection prevention strategies for these patients.
What could go wrong
This is a small, early-phase study that only measures immune response to a vaccine, not a treatment itself. Results may not apply to all patients or predict real-world infection risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

49 people

The number who actually took part.

Started

Aug 2020

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * CARTx RECIPIENTS: Patients must be capable of understanding and providing a written informed consent * CARTx RECIPIENTS: Patients must be 18 years of age or older, of any gender, race or ethnicity * CARTx RECIPIENTS: Patients must have had relapse-free survival for \>= 6 months after receiving CARTx for B-cell malignancies * CARTx RECIPIENTS: Platelet count \> 30,000 / mm\^3 * HEALTHY CONTROLS: Patients must be capable of understanding and providing a written informed consent * HEALTHY CONTROLS: Patients must be 18 years of age or older, of any gender, race or ethnicity Exclusion Criteria: * CARTx RECIPIENTS: Patients who have received a hematopoietic cell transplant after CARTx * CARTx RECIPIENTS: Previously received 1 or more rabies vaccines prior to the first vaccine visit * CARTx RECIPIENTS: Patients who have received lymphodepleting therapies after CARTx and within the past 6 months * CARTx RECIPIENTS: Patients with signs or symptoms of active infection * CARTx RECIPIENTS: Patients who are pregnant or breastfeeding * CARTx RECIPIENTS: Patients with previous known allergies to any component of the vaccine * CARTx RECIPIENTS: Patients who have previously experienced a reaction to any vaccine that required medical attention * CARTx RECIPIENTS: Study participants who report a severe adverse event following the first rabies vaccine will not be eligible for a second dose * CARTx RECIPIENTS: Receiving corticosteroids \> 0.5 mg/kg/day prednisone equivalence in the 7 days prior to first or second vaccination * HEALTHY CONTROLS: Previously received 1 or more rabies vaccines * HEALTHY CONTROLS: Chronic illness * HEALTHY CONTROLS: Signs or symptoms of active infection * HEALTHY CONTROLS: Pregnant or breastfeeding * HEALTHY CONTROLS: Patients with previous known allergies to any component of the vaccine * HEALTHY CONTROLS: Previous reaction to a vaccine that required medical attention

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-cell neoplasm are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.